Leeds Transplant Centre, St. James's University Hospital, Leeds, UK.
Department of Surgery and NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Transpl Int. 2017 Sep;30(9):884-892. doi: 10.1111/tri.12957. Epub 2017 May 2.
Transplant options for patients with type 1 diabetes and end-stage renal disease (ESRD) include deceased donor kidney, live donor kidney (LDK) and simultaneous pancreas-kidney (SPK) transplantation. The aim of this study was to compare outcomes between LDK and SPK for patients with type 1 diabetes and ESRD in the UK. Data on all SPK (n = 1739) and LDK (n = 385) transplants performed between January 2001 and December 2014 were obtained from the UK Transplant Registry. Unadjusted patient and kidney graft survival were calculated using the Kaplan-Meier method. Multivariate analysis of kidney graft and patient survival was performed using Cox proportional hazards regression. There was no significant difference in patient (P = 0.435) or kidney graft survival (P = 0.204) on univariate analysis. On multivariate analysis there was no association between LDK/SPK and patient survival [HR 0.71 (0.47-1.06), P = 0.095]. However, LDK was associated with an overall lower risk for kidney graft failure [HR 0.60 (0.38-0.94), P = 0.025]. SPK recipients with a functioning pancreas graft had significantly better kidney graft and patient survival than LDK recipients or those with a failed pancreas graft. SPK transplantation does not confer an overall survival advantage compared to LDK. However, those SPK recipients with a functioning pancreas have significantly better outcomes.
对于患有 1 型糖尿病和终末期肾病 (ESRD) 的患者,移植选择包括已故供体肾、活体供体肾 (LDK) 和同时胰腺肾 (SPK) 移植。本研究旨在比较英国 1 型糖尿病和 ESRD 患者 LDK 和 SPK 的结果。从英国移植登记处获得了 2001 年 1 月至 2014 年 12 月期间所有 SPK(n = 1739)和 LDK(n = 385)移植的数据。使用 Kaplan-Meier 方法计算未调整的患者和肾移植物存活率。使用 Cox 比例风险回归对肾移植物和患者存活率进行多变量分析。单变量分析时,患者(P = 0.435)或肾移植物存活率(P = 0.204)无显着差异。多变量分析时,LDK/SPK 与患者存活率之间无关联[HR 0.71(0.47-1.06),P = 0.095]。然而,LDK 与整体肾移植物衰竭风险降低相关[HR 0.60(0.38-0.94),P = 0.025]。具有功能胰腺移植物的 SPK 受者的肾移植物和患者存活率明显优于 LDK 受者或胰腺移植物衰竭的受者。与 LDK 相比,SPK 移植并没有带来整体生存优势。然而,那些具有功能胰腺的 SPK 受者的结局明显更好。